Paper Tools Add to my Library Share How would you like to share? Facebook Twitter LinkedIn Back to the Top
Mahase E. NICE rejects Alzheimer's drug donanemab owing to cost and "significant health risks". BMJ. 2024 Oct 23;387:q2342. PubMed. Recommends Please login to recommend the paper. Comments No Available Comments Make a Comment To make a comment you must login or register.
Comments
No Available Comments
Make a Comment
To make a comment you must login or register.